LISATA THERAPEUTICS, INC.
Close on Oct 19, 2026
- Market cap
- $9.11M
- P/E (TTM)
- –
- Dividend yield
- –
About Lisata Therapeutics
Pharmaceutical Preparations, SIC 2834
Lisata Therapeutics, Inc. is a clinical-stage pharmaceutical company focused on discovering, developing, and commercializing treatments for solid tumors and other serious conditions. The company's lead investigational drug candidate is certepetide, which operates via the C-end rule active transport pathway to facilitate deeper penetration of anti-cancer therapies into tumors while altering the tumor microenvironment. Lisata collaborates with biopharmaceutical partners and researchers to evaluate the drug alongside chemotherapy, immunotherapy, and RNA-based treatments for cancer patients.
The business operates as a Delaware corporation with its principal executive offices situated in Basking Ridge, New Jersey. In addition to domestic activities, Lisata conducts research collaborations, patent prosecutions, and clinical studies across multiple countries, including completed and ongoing trials in the United States, China, Australia, and New Zealand.
Summary of the business section of Lisata Therapeutics's latest annual report, written by StockData.
Company profile
Company
- Legal name
- LISATA THERAPEUTICS, INC.
- Founded
- 1980
- Headquarters
- Basking Ridge, NJ
- Address
- 110 Allen Road, Second Floor 07920
- Phone
- (908) 229-2590
- Website
- lisata.com
- Employees
- 21, Dec 31, 2025
- Industry
- Pharmaceutical Preparations
- Incorporated in
- Delaware
- Fiscal year ends
- December 31
- Auditor
- GRANT THORNTON LLP, New York, New York
Stock & identifiers
- Ticker
- LSTA
- Exchange
- Nasdaq
- Shares outstanding
- 9M, Aug 6, 2026
- Public float
- $23.60M, Jun 30, 2025
- Filer category
- Non-accelerated filer<br>Smaller reporting company
- Stock splits
- 1-for-15 reverse, Sep 15, 2022; 1-for-15 reverse, Sep 14, 2022; 1-for-10 reverse, Jul 28, 2016; 1-for-10 reverse, Jul 28, 2016; 1-for-10 reverse, Aug 8, 2013; 1-for-10 reverse, Jul 16, 2013; 1-for-10 reverse, Aug 9, 2007; 1-for-10 reverse, Aug 31, 2006
- SEC CIK
- 320017
- CUSIP
- 128058302
- ISIN
- US1280583022
- LEI
- 5493002287F62M3EGQ04
- EIN
- 22-2343568
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| David J. Mazzo | President & CEO, Director | 352,986 |
| Joshua Lehrer-Graiwer | President & COO | 27,808 |
| Tariq Imam | SVP, Bus Dev, General Counsel | 36,591 |
| Kristen K. Buck | EVP, R&D and CMO | 95,609 |
| James Nisco | SVP, Fin/Treas, Chief Actg Off | 32,311 |
| Ted W. Love | Director | 19,260 |
| Mohammad Azab | Director | 104,925 |
| Gregory B. Brown | Director | 95,659 |
| Cynthia Louise Flowers | Director | 95,446 |
| Heidi Henson | Director | 85,725 |
| Steven M. Klosk | Director | 95,815 |
CEO pay and shareholder return
Pay versus performance table from the proxy statement
| Fiscal year | CEO total pay | CEO pay actually paid | Other executives (avg) | Value of $100 invested | Peer group |
|---|---|---|---|---|---|
| FY2024 Dr. Mazzo | $1.69M | $1.68M | $790.61K | $24 | – |
| FY2023 Dr. Mazzo | $1.41M | $1.31M | $1.09M | $22 | – |
| FY2022 Dr. Mazzo | $1.93M | $1.26M | $720.14K | $20 | – |
“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.
Employees
Headcount reported in annual reports
“As of December 31, 2025, we had 21 full-time employees.”
Corporate history
Events identified from SEC filings